Press Releases

Company News
View Summary Global Adoption of Oncotype DX® Breast Cancer Test Continues to Grow with Achievement of Two Significant International Milestones
Apr 22, 2014
PDF 37.9 KB
View Summary Genomic Health Announces Presentation of New Data Further Supporting Use of Oncotype DX® in Europe
Mar 19, 2014
PDF 40.2 KB
View Summary Genomic Health Announces Year-End 2013 Financial Results, Provides 2014 Financial Outlook
Feb 4, 2014
PDF 28.8 KB
View Summary Genomic Health Announces Results of Oncotype DX® Colon Cancer Studies Presented at 2014 American Society of Clinical Oncology Gastrointestinal Cancer (ASCO GI) Symposium
Jan 29, 2014
PDF 18.6 KB
View Summary Genomic Health to Announce Fourth Quarter and Year-End 2013 Financial Results and Host Conference Call on Tuesday, February 4, 2014
Jan 28, 2014
PDF 16.1 KB
View Summary Genomic Health Announces Presentation at J.P. Morgan Healthcare Conference
Jan 6, 2014
PDF 15.5 KB
View Summary Genomic Health Announces Presentation of New Oncotype DX® Studies Underscoring Unique Value of the Test in Early-Stage Breast Cancer at the 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium
Dec 14, 2013
PDF 20.4 KB
View Summary Genomic Health Announces Presentation of Oncotype DX® Studies at the 2013 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS)
Dec 4, 2013
PDF 17.6 KB
View Summary Genomic Health and Almac Group Enter Exclusive In-Licensing Agreement to Develop and Commercialize Anthracycline Chemotherapy Benefit Test for High Risk Breast Cancer
Nov 25, 2013
PDF 28.2 KB
View Summary Genomic Health Announces Publication of Oncotype DX® Prostate Cancer Test Analytical Validation Study
Nov 22, 2013
PDF 17.2 KB
View Summary Genomic Health Announces Colon Cancer Publication in Journal of Clinical Oncology Supporting Wider Oncotype DX® Utilization
Nov 13, 2013
PDF 17.6 KB
View Summary Genomic Health Announces Third Quarter 2013 Financial Results and Business Progress
Nov 5, 2013
PDF 27.4 KB
View Summary Genomic Health Announces Colon Cancer Publication Supporting Wider Oncotype DX® Utilization
Nov 5, 2013
PDF 18.1 KB
View Summary Genomic Health to Announce Third Quarter 2013 Financial Results and Host Conference Call on Tuesday, November 5, 2013
Oct 29, 2013
PDF 15.4 KB
View Summary Genomic Health Announces Presentation of Oncotype DX® Studies Reinforcing Value of Tests in Guiding Treatment for Multiple Cancers
Oct 1, 2013
PDF 23.3 KB
View Summary NICE Recommends Genomic Health's Oncotype DX® Test To Guide Chemotherapy Treatment Decisions For Qualified Early-Stage Invasive Breast Cancer Patients
Sep 25, 2013
PDF 18.4 KB
View Summary Updated St. Gallen International Breast Cancer Guidelines, for the Second Time, Recognize Oncotype DX® as the Only Validated Multi-Gene Test Able to Predict Chemotherapy Benefit
Aug 22, 2013
PDF 18.1 KB
View Summary Genomic Health to Present at the Canaccord Genuity 33rd Annual Growth Conference
Aug 7, 2013
PDF 14.6 KB
View Summary Genomic Health Announces Second Quarter 2013 Financial Results and Business Progress
Jul 31, 2013
PDF 26.8 KB
View Summary Genomic Health to Announce Second Quarter 2013 Financial Results and Host Conference Call on Wednesday, July 31, 2013
Jul 24, 2013
PDF 15.0 KB
Showing 1-20 of 270 Page: 1 2 3 4 5 ... 14  Next 20


  • ASCO® is a registered trademark of the American Society of Clinical Oncology. ASCO does not endorse any product or therapy. ® is a registered trademark of the National Comprehensive Cancer Network. The NCCN does not endorse any product or therapy.

Contact Information

For Investors:
650.569.2281
investors@genomichealth.com

For Media:
650.569.2215
media@genomichealth.com

Email Alerts

To sign-up to receive email alerts for press releases, stock information, new calendar events and/or SEC filings click here.

Shareholder Tools



DISCLAIMER

The information in the fact sheet, press releases and webcasts should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.

Forward-Looking Statements

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties associated with the reimbursement for and adoption of Oncotype DX; commercialization of any future tests; the nature and sources of our revenues; our dependence on collaborative relationships; the regulation of Oncotype DX or any future tests we may develop by the FDA; the attributes of our products; the benefits of personalized medicine and its ability to impact treatment decisions; the outcome and success of clinical trials; the applicability of clinical results to actual outcomes; the company's beliefs regarding the potential benefits that may be obtained from additional tests; and other factors detailed from time to time in Genomic Health's periodic filings with the Securities and Exchange Commission. Genomic Health, Inc. specifically disclaims any obligation to update any forward-looking statements.